{
    "id": 2876,
    "fullName": "PLK1 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "PLK1 over exp indicates an over expression of the Plk1 protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 5347,
        "geneSymbol": "PLK1",
        "terms": [
            "PLK1",
            "PLK",
            "STPK13"
        ]
    },
    "variant": "over exp",
    "createDate": "01/02/2015",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 1578,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BI2536 treatment inhibited growth of patient-derived PLK1-overexpressing medulloblastoma cells in culture (PMID: 24019381)",
            "molecularProfile": {
                "id": 2700,
                "profileName": "PLK1 over exp"
            },
            "therapy": {
                "id": 676,
                "therapyName": "BI2536",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1559,
                    "pubMedId": 24019381,
                    "title": "Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24019381"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2390,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human pancreatic cancer cells over expressing PLK1 demonstrated a significant decrease in tumor size in xenograft models when treated with a combination of Rigosertib (ON01910) and Gemzar (gemcitabine) (PMID: 15766665).",
            "molecularProfile": {
                "id": 2700,
                "profileName": "PLK1 over exp"
            },
            "therapy": {
                "id": 2823,
                "therapyName": "Gemcitabine + Rigosertib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 2980,
                    "pubMedId": 15766665,
                    "title": "ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15766665"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3669,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BI2536 and Metformin worked synergistically to induce apoptosis and inhibit growth of PLK1-over expressing prostate cancer cells with wild-type TP53 in cell culture and in PDX models (PMID: 25505174).",
            "molecularProfile": {
                "id": 14280,
                "profileName": "PLK1 over exp TP53 wild-type"
            },
            "therapy": {
                "id": 3223,
                "therapyName": "BI2536 + Metformin",
                "synonyms": null
            },
            "indication": {
                "id": 10286,
                "name": "prostate carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3947,
                    "pubMedId": 25505174,
                    "title": "Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25505174"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3670,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreased expression of Tp53 in Plk1-over expressing prostate carcinoma cell lines resulted in decreased response to growth inhibition by the combination of BI2536 and Metformin in culture (PMID: 25505174).",
            "molecularProfile": {
                "id": 14282,
                "profileName": "PLK1 over exp TP53 dec exp"
            },
            "therapy": {
                "id": 3223,
                "therapyName": "BI2536 + Metformin",
                "synonyms": null
            },
            "indication": {
                "id": 10286,
                "name": "prostate carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3947,
                    "pubMedId": 25505174,
                    "title": "Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25505174"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5270,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a human melanoma cell line harboring NRAS G12D with PLK1 over expression was sensitive to the combination of Mekinist (trametinib) and Volasertib, which produced a synergistic effect in xenograft models, resulting in decreased cell viability and tumor regression (PMID: 26016894).",
            "molecularProfile": {
                "id": 20450,
                "profileName": "NRAS G12D PLK1 over exp"
            },
            "therapy": {
                "id": 3805,
                "therapyName": "Trametinib + Volasertib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4976,
                    "pubMedId": 26016894,
                    "title": "Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26016894"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5269,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a human melanoma cell line harboring NRAS Q61K with PLK1 over expression was sensitive to the combination of Mekinist (trametinib) and Volasertib, which produced a synergistic effect in cell line xenograft models, resulting in decreased cell viability and tumor regression (PMID: 26016894).",
            "molecularProfile": {
                "id": 20451,
                "profileName": "NRAS Q61K PLK1 over exp"
            },
            "therapy": {
                "id": 3805,
                "therapyName": "Trametinib + Volasertib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4976,
                    "pubMedId": 26016894,
                    "title": "Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26016894"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2700,
            "profileName": "PLK1 over exp",
            "profileTreatmentApproaches": [
                {
                    "id": 5288,
                    "name": "PLK1 Inhibitor",
                    "profileName": "PLK1 over exp"
                }
            ]
        },
        {
            "id": 14280,
            "profileName": "PLK1 over exp TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 14282,
            "profileName": "PLK1 over exp TP53 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20450,
            "profileName": "NRAS G12D PLK1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20451,
            "profileName": "NRAS Q61K PLK1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}